American Journal of Psychiatry · 1999 · 128 citations · 15 references
MedicinePharmacologyPharmacotherapyDementiaNeuropharmacologyPsychopharmacologyAlzheimer DiseaseCognitive ImpairmentDementia PharmacotherapyDementia TreatmentGlutamatergic NeurochemistryGlutamatergic PharmacologyAlzheimer Disease DementiaMedication Effects On CognitionN-methyl-d-aspartate Receptor AntagonismN-methyl-d-aspartate Receptor InhibitionPharmacological Treatment Of DementiaPlacebo-controlled Efficacy Assessment
OBJECTIVE: Glutamatergic neurotransmission is important for memory and cognition and is severely affected in Alzheimer's disease. D-Cycloserine exhibits partial agonist activity at the glycine site of N-methyl-D-aspartate subtype glutamate receptor, facilitating activation of the receptor and improving cognition and memory. METHOD: Seventeen patients with Alzheimer's disease received a three-phase, double-blind, placebo-controlled trial of 50 mg and 100 mg/day of D-cycloserine. RESULTS: D-Cycloserine was associated with significant improvement in scores on the cognitive subscale of the Alzheimer's Disease Assessment Scale (improvement of 3.0 points) when given at a dose of 100 mg/day. CONCLUSIONS: D-Cycloserine has cognitive benefits for patients with Alzheimer's disease.
15
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
Cerebral Blood Flow in Dementia
Vladimir Hachinski, L. D. Iliff, E. Zilhka et al. · Archives of Neurology · 1975 · 3.2K citations
Medicine, Neurology, Neuroscience +14
d-Cycloserine enhances implicit memory in Alzheimer patients
Barbara L. Schwartz, Shahin Hashtroudi, Robert L. Herting et al. · Neurology · 1996 · 149 citations
Medicine, Neurology, Pharmacology +16